Source comparison
BPC-157 vs Standard UC Therapies: Mechanism Comparison
BPC-157 (research peptide) Nitric oxide modulation + VEGF upregulation Direct angiogenesis stimulation at injury sites Oral, subcutaneous, intraperitoneal (preclinical only) 7–14 days in rodent models Preclinical only. No human RCTs 5-ASA (mesalamine) Prostagl
This comparison does not assign a generated winner or score.
- BPC-157 (research peptide)
- Nitric oxide modulation + VEGF upregulation
- Direct angiogenesis stimulation at injury sites
- Oral, subcutaneous, intraperitoneal (preclinical only)
- 7–14 days in rodent models
- Preclinical only. No human RCTs
- 5-ASA (mesalamine)
- Prostaglandin synthesis inhibition
- Indirect. Reduces inflammation allowing passive repair
- Oral, rectal suppository
- 2–4 weeks for symptom improvement
- Multiple Phase III RCTs, FDA-approved
- Corticosteroids (prednisone)
- Broad immune suppression via glucocorticoid receptor
- Indirect. Suppresses immune-driven tissue damage
- Oral, IV, rectal
- 3–7 days for acute flare control
- Established standard of care. Decades of clinical use
- Anti-TNF biologics (infliximab)
- TNF-alpha receptor antagonism
- Indirect. Blocks cytokine-driven inflammation
- IV infusion every 8 weeks after loading
- 4–8 weeks for mucosal healing
- Phase III RCTs, FDA-approved for moderate-severe UC
- BPC-157
- Growth factor–driven tissue regeneration
- Direct fibroblast migration + collagen synthesis
- Not established in humans
- Unknown in clinical context
- No human trials published